Molecular target therapies in endometrial cancer: from the basic research to the clinic.
about
The role of surgery in recurrent endometrial cancer.Molecular profiling of endometrial malignancies.Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experienceKnockdown of MTDH sensitizes endometrial cancer cells to cell death induction by death receptor ligand TRAIL and HDAC inhibitor LBH589 co-treatment.Mammalian target of rapamycin complex 1 and cyclooxygenase 2 pathways cooperatively exacerbate endometrial cancer.Effect of mTOR inhibitors in nude mice with endometrial carcinoma and variable PTEN expression status.Cancer-associated fibroblasts promote proliferation of endometrial cancer cellsClinicopathological significance of claudin 4 expression in gastric carcinoma: a systematic review and meta-analysis.The roles of tricellular tight junction protein lipolysis-stimulated lipoprotein receptor in malignancy of human endometrial cancer cellsExpression of metabolically targeted biomarkers in endometrial carcinoma.Tight junctions: a barrier to the initiation and progression of breast cancer?Evaluation of expression of the PTEN gene, oestrogen and progesterone receptors as diagnostic and predictive factors in endometrial cancer.Pharmacotherapy of endometrial cancer.PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer.Role of epigenomics in ovarian and endometrial cancers.Regulation of tight junctions by sex hormones in normal human endometrial epithelial cells and uterus cancer cell line Sawano.EGFR- and AKT-mediated reduction in PTEN expression contributes to tyrphostin resistance and is reversed by mTOR inhibition in endometrial cancer cells.Expression of Glut-1 in Normal Endometrium and Endometrial Lesions: Analysis of 336 Cases.
P2860
Q30249789-698F12FB-40AC-4173-88EE-4B73D479AC77Q33757898-A725C670-AA50-41DE-B9A2-46BA9D379BBEQ33899157-D8D4D1BA-CB68-482B-8DDE-0B50BD317E80Q33936620-A136D9F2-ADB1-4E3C-9C62-5112A320A083Q34299944-1F98F1B4-F4E4-4002-A77F-8F21F09BD6EFQ34306540-9B62FA4C-6CFB-48CD-A08B-B26ECCE9C20EQ34901877-E3F8E4DD-4C60-4151-A398-1FD0809CCB83Q36967957-49A056E2-C549-4C08-A8B7-78F03EB49FDDQ37317381-FCAB7AD9-534C-49B6-8E85-502B14E5EB2AQ37340072-1A118FA5-CF5B-42DD-97A3-101E2BBB7643Q37420725-6C8FC228-EC5B-4B3F-BAA8-A281AD652473Q37471173-10FFB1AE-ED2A-4C07-8683-9628B5D4883AQ37544822-A29A4947-22B2-4AC0-B474-61E00E44E62DQ37707021-C9AB649F-E2DB-4A12-815B-AB932067433EQ37961734-120D75D2-5E7E-49D4-B5D1-CF7FB7305C36Q39131438-CBB3AA7D-40B4-4319-BAA7-544AC3EA4BB1Q39467200-E23AA292-8539-47AD-AA6C-48F17426D2CEQ51070213-9307D5DA-9610-4F15-A779-4BCC1FFDC857
P2860
Molecular target therapies in endometrial cancer: from the basic research to the clinic.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Molecular target therapies in endometrial cancer: from the basic research to the clinic.
@en
Molecular target therapies in endometrial cancer: from the basic research to the clinic.
@nl
type
label
Molecular target therapies in endometrial cancer: from the basic research to the clinic.
@en
Molecular target therapies in endometrial cancer: from the basic research to the clinic.
@nl
prefLabel
Molecular target therapies in endometrial cancer: from the basic research to the clinic.
@en
Molecular target therapies in endometrial cancer: from the basic research to the clinic.
@nl
P2093
P2860
P1476
Molecular target therapies in endometrial cancer: from the basic research to the clinic
@en
P2093
Andrea Riccardo Genazzani
Antonio Fanucchi
Roberta Tana
Stefania Cosio
P2860
P304
P356
10.1080/09513590801953556
P577
2008-05-01T00:00:00Z